Jonathan Wolleben
Stock Analyst at JMP Securities
(4.10)
# 455
Out of 4,853 analysts
195
Total ratings
46.77%
Success rate
13.43%
Average return
Main Sectors:
Stocks Rated by Jonathan Wolleben
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DBVT DBV Technologies | Maintains: Market Outperform | $15 → $21 | $8.51 | +146.77% | 14 | May 27, 2025 | |
| AURA Aura Biosciences | Reiterates: Market Outperform | $19 | $6.10 | +211.48% | 8 | May 23, 2025 | |
| CLSD Clearside Biomedical | Reiterates: Market Outperform | $5 | $0.78 | +545.16% | 11 | May 16, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Market Outperform | $74 → $76 | $44.65 | +70.21% | 10 | May 9, 2025 | |
| MDGL Madrigal Pharmaceuticals | Reiterates: Market Outperform | $443 | $274.10 | +61.62% | 12 | Apr 24, 2025 | |
| MBX MBX Biosciences | Initiates: Market Outperform | $38 | $11.86 | +220.40% | 1 | Apr 10, 2025 | |
| ALT Altimmune | Reiterates: Market Outperform | $25 | $5.46 | +357.88% | 12 | Apr 2, 2025 | |
| KALV KalVista Pharmaceuticals | Reiterates: Market Outperform | $19 | $13.80 | +37.68% | 3 | Mar 26, 2025 | |
| SKYE Skye Bioscience | Reiterates: Market Outperform | $15 | $2.15 | +597.67% | 2 | Mar 21, 2025 | |
| PTGX Protagonist Therapeutics | Reiterates: Market Outperform | $61 | $53.82 | +13.34% | 11 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $22 → $19 | $8.46 | +124.59% | 17 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $55 | $16.23 | +238.98% | 11 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $18 | $10.98 | +63.93% | 7 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $26 | $5.22 | +398.08% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $91 → $87 | $21.47 | +305.22% | 8 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $92 → $91 | $32.29 | +181.82% | 14 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $75 | $66.18 | +13.33% | 2 | Dec 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $9 | $2.38 | +278.15% | 8 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $55 → $50 | $39.03 | +28.11% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $90 | $78.20 | +15.09% | 1 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $137.29 | - | 1 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $8 | $1.80 | +344.44% | 7 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Accumulate | $420 → $485 | $712.82 | -31.96% | 1 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $48 → $32 | $4.78 | +569.46% | 8 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $25 | $2.46 | +916.26% | 11 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $8 | $0.34 | +2,258.49% | 11 | Apr 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $24 | $26.21 | -8.43% | 1 | May 12, 2023 |
DBV Technologies
May 27, 2025
Maintains: Market Outperform
Price Target: $15 → $21
Current: $8.51
Upside: +146.77%
Aura Biosciences
May 23, 2025
Reiterates: Market Outperform
Price Target: $19
Current: $6.10
Upside: +211.48%
Clearside Biomedical
May 16, 2025
Reiterates: Market Outperform
Price Target: $5
Current: $0.78
Upside: +545.16%
Mirum Pharmaceuticals
May 9, 2025
Maintains: Market Outperform
Price Target: $74 → $76
Current: $44.65
Upside: +70.21%
Madrigal Pharmaceuticals
Apr 24, 2025
Reiterates: Market Outperform
Price Target: $443
Current: $274.10
Upside: +61.62%
MBX Biosciences
Apr 10, 2025
Initiates: Market Outperform
Price Target: $38
Current: $11.86
Upside: +220.40%
Altimmune
Apr 2, 2025
Reiterates: Market Outperform
Price Target: $25
Current: $5.46
Upside: +357.88%
KalVista Pharmaceuticals
Mar 26, 2025
Reiterates: Market Outperform
Price Target: $19
Current: $13.80
Upside: +37.68%
Skye Bioscience
Mar 21, 2025
Reiterates: Market Outperform
Price Target: $15
Current: $2.15
Upside: +597.67%
Protagonist Therapeutics
Mar 10, 2025
Reiterates: Market Outperform
Price Target: $61
Current: $53.82
Upside: +13.34%
Mar 4, 2025
Maintains: Market Outperform
Price Target: $22 → $19
Current: $8.46
Upside: +124.59%
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $55
Current: $16.23
Upside: +238.98%
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $10.98
Upside: +63.93%
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $26
Current: $5.22
Upside: +398.08%
Feb 28, 2025
Maintains: Market Outperform
Price Target: $91 → $87
Current: $21.47
Upside: +305.22%
Feb 28, 2025
Maintains: Market Outperform
Price Target: $92 → $91
Current: $32.29
Upside: +181.82%
Dec 23, 2024
Reiterates: Market Outperform
Price Target: $75
Current: $66.18
Upside: +13.33%
Dec 19, 2024
Reiterates: Market Outperform
Price Target: $9
Current: $2.38
Upside: +278.15%
Dec 18, 2024
Maintains: Market Outperform
Price Target: $55 → $50
Current: $39.03
Upside: +28.11%
Dec 16, 2024
Reiterates: Market Outperform
Price Target: $90
Current: $78.20
Upside: +15.09%
Dec 16, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $137.29
Upside: -
Dec 12, 2024
Reiterates: Market Outperform
Price Target: $8
Current: $1.80
Upside: +344.44%
Nov 13, 2024
Downgrades: Accumulate
Price Target: $420 → $485
Current: $712.82
Upside: -31.96%
Aug 15, 2024
Maintains: Market Outperform
Price Target: $48 → $32
Current: $4.78
Upside: +569.46%
May 31, 2024
Reiterates: Market Outperform
Price Target: $25
Current: $2.46
Upside: +916.26%
Apr 19, 2024
Reiterates: Market Outperform
Price Target: $8
Current: $0.34
Upside: +2,258.49%
May 12, 2023
Maintains: Outperform
Price Target: $25 → $24
Current: $26.21
Upside: -8.43%